Toll-like receptor 2-mediated modulation of growth and functions of regulatory T cells by oral streptococci

2013 ◽  
Vol 28 (4) ◽  
pp. 267-280 ◽  
Author(s):  
A. Saeki ◽  
T. Segawa ◽  
T. Abe ◽  
M. Sugiyama ◽  
T. Arimoto ◽  
...  
2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Ruud P. H. Raijmakers ◽  
Evelien G. G. Sprenkeler ◽  
Floor E. Aleva ◽  
Cor W. M. Jacobs ◽  
Thirumala-Devi Kanneganti ◽  
...  

2016 ◽  
Vol 29 (6) ◽  
pp. 322-331 ◽  
Author(s):  
Xin Liu ◽  
Jing-Hui Guan ◽  
Ben-Chun Jiang ◽  
Zhen-Sheng-Nan Li ◽  
Guang-Ze Zhu

2004 ◽  
Vol 172 (6) ◽  
pp. 3712-3718 ◽  
Author(s):  
Mihai G. Netea ◽  
Roger Sutmuller ◽  
Corinna Hermann ◽  
Chantal A. A. Van der Graaf ◽  
Jos W. M. Van der Meer ◽  
...  

2020 ◽  
Vol 48 (12) ◽  
pp. 030006052098094
Author(s):  
Shuang Qin ◽  
Li Li ◽  
Jia Liu ◽  
Jinrui Zhang ◽  
Qing Xiao ◽  
...  

Objective The present study aimed to evaluate the effects of cluster of differentiation (CD)4+CD25+ forkhead box p3 (Foxp3)+ regulatory T cells (Tregs) on unexplained recurrent spontaneous abortion (URSA) and the associated mechanisms. Methods The proportion of CD4+CD25+Foxp3+ Tregs and inflammatory cytokine concentrations in the peripheral blood of women with URSA were measured by flow cytometry and enzyme-linked immunosorbent assay, respectively. CBA/JxDBA/2J mating was used to establish an abortion-prone mouse model and the model mice were treated with the Toll-like receptor 4 (TLR4) antagonist E5564 and the TLR4 agonist lipopolysaccharide. Results The proportion of CD4+CD25+Foxp3+ Tregs was decreased and the inflammatory response was increased in women with URSA. In the abortion-prone mouse model, E5564 significantly increased the proportion of CD4+CD25+Foxp3+ Tregs, decreased the inflammatory response, and increased Foxp3 mRNA and protein expression. Lipopolysaccharide had adverse effects on the abortion-prone model. Conclusions These data suggest that CD4+CD25+Foxp3+ Tregs regulate immune homeostasis in URSA via the TLR4/nuclear factor-κB pathway, and that the TLR4 antagonist E5564 may be a novel and potential drug for treating URSA.


Sign in / Sign up

Export Citation Format

Share Document